The study reviews CAR-T cell advancements in lymphoma treatment, addressing T cell exhaustion and tumor immune evasion with next-generation CAR modifications.

CAR-T cells, which are genetically programmed to specifically recognize and kill target cells, have altered the therapeutic landscape of lymphoma.

SAN DIEGO-- (BUSINESS WIRE)--Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using CellSeeker™, a targeted ...

Effect of ICV delivered CAR-T cells for UPN145 and patient overall survival and quality-of-life evaluations. Credit: Nature Medicine (2024). DOI: 10.1038/s41591-024-02875-1 ...

(MEMPHIS, Tenn. – November 30, 2023) Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for pediatric patients with relapsed and recurrent ...

Engineering chimeric antigen receptor (CAR) with intracellular fragment of CTLA-4 enhances CAR-T antitumor activity Cellinfinity has exclusively licensed the CTLA-4 tail technology for development ...

Advances in harnessing the immune system to treat cancer have defined the past decade of progress in oncology. Chimeric antigen receptor (CAR) T-cells are a type of cellular immunotherapy created by ...

Chimeric antigen receptor (CAR) therapies utilize engineered receptors that are able to redirect immune cells to identify and destroy cancer cells that express a specific antigen. At present, CAR ...

B-cell maturation antigen (BCMA) is widely expressed on the surface of mature B cells, normal and malignant plasma cells, but has low expression on other normal cells and no expression on CD34 + ...

CARs are synthetic receptors that redirect the specificity, function, and metabolism of T cells (Figure 2). CARs consist of a T-cell activating domain (typically including the zeta chain of the ...